PRESS RELEASE published on 03/28/2025 at 21:07, 1 year 4 months ago Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran) approved as the first US therapy for hemophilia A or B with or without inhibitors, offering consistent protection with few injections, using unique mechanism to reduce bleeding episodes Fitusiran Hemophilia Qfitlia Antithrombin-lowering Therapy Bleed Protection
BRIEF published on 03/28/2025 at 07:05, 1 year 4 months ago Dupixent Approved in Japan as First Biologic for COPD Japan Dupixent COPD Treatment Sanofi-Aventis Biologic Approval
PRESS RELEASE published on 03/28/2025 at 07:00, 1 year 4 months ago Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD Japan COPD Dupixent Phase 3 Results Biologic Medicine
PRESS RELEASE published on 03/24/2025 at 19:27, 1 year 4 months ago Sanofi: Disclosure of trading in own shares
BRIEF published on 03/24/2025 at 07:35, 1 year 4 months ago Sanofi launches the “Q1 2025 Aide mémoire” document Financial Results Investors Sanofi Q1 2025 Memory Aid
PRESS RELEASE published on 03/24/2025 at 07:30, 1 year 4 months ago Press Release: Availability of the Q1 2025 Aide mémoire Sanofi announced the availability of the Q1 2025 Aide mémoire on its website to assist in financial modeling, including non-comparable items and first quarter reminders Sanofi Financial Modeling Aide Mémoire Q1 2025 Exclusivity Losses
PRESS RELEASE published on 03/10/2025 at 21:09, 1 year 4 months ago Sanofi: Disclosure of trading in own shares
BRIEF published on 03/08/2025 at 19:05, 1 year 4 months ago Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
PRESS RELEASE published on 03/08/2025 at 19:00, 1 year 4 months ago Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF published on 02/25/2025 at 07:05, 1 year 5 months ago Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
Published on 08/01/2026 at 01:20, 2 days 20 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 20 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 21 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 2 days 22 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/03/2026 at 19:35, 1 hour 57 minutes ago Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
Published on 08/03/2026 at 19:01, 2 hours 31 minutes ago EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026
Published on 08/03/2026 at 18:45, 2 hours 47 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 17:45, 3 hours 47 minutes ago Monthly disclosure of the total number of shares and voting rights - July 2026
Published on 08/03/2026 at 17:40, 3 hours 52 minutes ago Eiffage announces the end of exclusive negotiations with Atlas Arteria for the possible acquisition of the Warnow Tunnel concession in Rostock, Germany